Who are Docetaxel or albumin paclitaxel's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Paclitaxel (albumin-bound), Paclitaxel, Epirubicin, Docetaxel (DOC), nab-paclitaxel，Cisplatin, Paclitaxel injection, docetaxel and cisplatin.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/docetaxel-or-albumin-paclitaxel.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Docetaxel or albumin paclitaxel — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Docetaxel or albumin paclitaxel (Docetaxel or albumin paclitaxel) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Taxane; microtubule-stabilizing chemotherapy agent. Area: Oncology.

marketed Taxane; microtubule-stabilizing chemotherapy agent β-tubulin (microtubule) Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Docetaxel or albumin paclitaxel (Docetaxel or albumin paclitaxel) — Shandong Cancer Hospital and Institute. Docetaxel and albumin-bound paclitaxel are taxane chemotherapy agents that stabilize microtubules by binding to β-tubulin, preventing their depolymerization and causing cell cycle arrest and apoptosis.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Docetaxel or albumin paclitaxel TARGET	Docetaxel or albumin paclitaxel	Shandong Cancer Hospital and Institute	marketed	Taxane; microtubule-stabilizing chemotherapy agent	β-tubulin (microtubule)
Paclitaxel (albumin-bound)	Paclitaxel (albumin-bound)	Dai, Guanghai	marketed	Taxane; microtubule stabilizer	β-tubulin (microtubule)
Paclitaxel, Epirubicin	Paclitaxel, Epirubicin	Tianjin Medical University Cancer Institute and Hospital	marketed	Chemotherapy combination (taxane + anthracycline)	Microtubules (paclitaxel); Topoisomerase II and DNA (epirubicin)
Docetaxel (DOC)	Docetaxel (DOC)	Sun Yat-sen University	marketed	Taxane; microtubule stabilizer	β-tubulin
nab-paclitaxel，Cisplatin	nab-paclitaxel，Cisplatin	Yang Jianjun, PhD	marketed	Chemotherapy combination (taxane + platinum agent)	Microtubules (paclitaxel); DNA (cisplatin)
Paclitaxel injection	Paclitaxel injection	Guangzhou Double Bioproducts Co., Ltd	marketed	Taxane; microtubule stabilizer	β-tubulin
docetaxel and cisplatin	docetaxel and cisplatin	Sanofi	marketed	Chemotherapy combination (taxane + platinum agent)	Microtubules (docetaxel); DNA (cisplatin)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Taxane; microtubule-stabilizing chemotherapy agent class)

Shandong Cancer Hospital and Institute · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Docetaxel or albumin paclitaxel — Competitive Intelligence Brief. https://druglandscape.com/ci/docetaxel-or-albumin-paclitaxel. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab